ApicHope(SZ:300723) Xin Lang Zheng Quan·2026-01-05 14:45Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has announced the progress of its share repurchase plan, indicating that as of December 31, 2025, it has repurchased 2.6932 million shares, accounting for 0.60% of its total share capital, with a total expenditure of 93.8909 million yuan, nearing the lower limit of the repurchase plan of 100 million yuan [1][3]. Group 1: Repurchase Plan Background - The board of directors approved a share repurchase plan on December 15, 2025, intending to use self-owned and/or raised funds to repurchase A-shares through centralized bidding to maintain company value and shareholder rights [2]. - The repurchase plan sets a total fund range of no less than 100 million yuan and no more than 200 million yuan, with a maximum repurchase price of 70 yuan per share, and the implementation period is within three months from the board's approval [2]. Group 2: Repurchase Progress Details - As of December 31, 2025, the company has repurchased 2.6932 million shares through a dedicated securities account via centralized bidding, with the highest transaction price at 37.72 yuan per share, the lowest at 32.15 yuan per share, and an average transaction price of 34.86 yuan per share, totaling 93.8909 million yuan spent (excluding fees) [3]. - The repurchase actions comply with the established plan and relevant legal regulations, adhering to trading time and other restrictions as per the regulations [3]. Group 3: Future Arrangements - The company plans to continue implementing the share repurchase plan based on market conditions within the designated period and will fulfill its information disclosure obligations as required by laws and regulations [4]. - The implementation of this repurchase plan reflects the company's recognition of its value and confidence in future development, aiming to maintain shareholder rights and stabilize market expectations [4].